Platelet aggregation at high shear is impaired in patients with congenital defects of platelet secretion and is corrected by DDAVP: correlation with the bleeding time
- PMID: 7706911
Platelet aggregation at high shear is impaired in patients with congenital defects of platelet secretion and is corrected by DDAVP: correlation with the bleeding time
Abstract
Techniques measuring platelet aggregation in vitro under the high shear rate conditions that can be found in the microcirculation could reflect the status of primary hemostasis better than the turbidimetric technique. We studied platelet aggregation at high shear in patients with prolonged bleeding time caused by congenital platelet secretion defects such as delta-storage pool deficiency and primary secretion defect. Two different techniques were used: shear-induced platelet aggregation in a cone-and-plate viscometer and the filter aggregation test. With both techniques, platelet aggregation at high shear rate was defective in 14 patients with delta-storage pool deficiency and in 8 with primary secretion defect. There was a statistically significant correlation between platelet aggregation at high shear rate and the bleeding time. In patients with delta-storage pool deficiency, platelet aggregation at high shear rate and the bleeding time were significantly correlated with the platelet serotonin content. The intravenous infusion of 1-deamino-8-D-arginine vasopressin (DDAVP) (0.3 micrograms/kg) increased the plasma concentration of von Willebrand factor (vWf), shortened the bleeding time, and potentiated platelet aggregation at high shear rate in all patients. Because platelet aggregation at high shear rate requires vWf, the effect of DDAVP is probably due to the induced increase in plasma vWf. Therefore, platelet aggregation at high shear rate is defective in patients with congenital defects of platelet secretion and is potentiated by DDAVP. Potentiation of platelet aggregation at high shear rate may be one mechanism by which DDAVP shortens the prolonged bleeding time of patients with congenital defects of platelet secretion.
Similar articles
-
Role of ADP in platelet aggregation at high shear: studies in a patient with congenital defect of platelet responses to ADP.Br J Haematol. 1994 Dec;88(4):826-9. doi: 10.1111/j.1365-2141.1994.tb05123.x. Br J Haematol. 1994. PMID: 7819105
-
[Utility of desmopressin in 4 cases of thrombocytopathies associated with giant platelets].Rev Invest Clin. 1997 Jul-Aug;49(4):281-6. Rev Invest Clin. 1997. PMID: 9707993 Spanish.
-
Mechanisms of platelet dysfunction and response to DDAVP in patients with congenital platelet function defects. A double-blind placebo-controlled trial.Thromb Haemost. 1995 Oct;74(4):1071-8. Thromb Haemost. 1995. PMID: 8560416 Clinical Trial.
-
Laboratory diagnosis and molecular classification of von Willebrand disease.Acta Haematol. 2009;121(2-3):71-84. doi: 10.1159/000214846. Epub 2009 Jun 8. Acta Haematol. 2009. PMID: 19506352 Review.
-
The paradox of platelet activation and impaired function: platelet-von Willebrand factor interactions, and the etiology of thrombotic and hemorrhagic manifestations in essential thrombocythemia and polycythemia vera.Semin Thromb Hemost. 2006 Sep;32(6):589-604. doi: 10.1055/s-2006-949664. Semin Thromb Hemost. 2006. PMID: 16977569 Review.
Cited by
-
[Therapeutic options for perioperatively acquired platelet dysfunctions].Anaesthesist. 2009 Sep;58(9):931-2, 934-6, 938-40. doi: 10.1007/s00101-009-1599-8. Anaesthesist. 2009. PMID: 19727578 Review. German.
-
A Review of Desmopressin Use in Bleeding Disorders: An Unsung Hero?Biomolecules. 2025 Jul 5;15(7):967. doi: 10.3390/biom15070967. Biomolecules. 2025. PMID: 40723839 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Medical
Miscellaneous